Biopsy Devices Breast Biopsy Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The breast biopsy devices market covers the hardware and consumables used to perform core needle, fine needle aspiration, vacuum-assisted, and image-guided breast tissue sampling. Demand is anchored by the global burden of breast cancer, which remains the most commonly diagnosed cancer in women worldwide. Growth is reinforced by national mammography screening initiatives and the migration of biopsy procedures from operating rooms to outpatient radiology suites.

• •Market size in 2025 is estimated at approximately USD 7.91 billion.
• •Forecast compound annual growth rate is around 5.8% per year.
• •Demand is driven by rising breast cancer incidence and expanded screening coverage.

Rising breast cancer prevalence, an aging female population, and earlier detection through routine mammography are the leading demand drivers. Technological advances such as vacuum-assisted excision, digital tomosynthesis-guided sampling, and MRI- and ultrasound-guided systems are improving diagnostic yield while reducing procedure invasiveness. Reimbursement support for minimally invasive biopsies, alongside growing patient preference for outpatient and same-day procedures, further accelerates market expansion.

• •Increasing global breast cancer incidence and earlier detection raise biopsy volumes.
• •Adoption of vacuum-assisted and image-guided techniques improves diagnostic accuracy.
• •Favorable reimbursement and patient preference for minimally invasive outpatient procedures support growth.

By product, the market is segmented into core needle biopsy devices, vacuum-assisted biopsy systems, fine needle aspiration biopsy devices, and biopsy guidance systems, with core needle and vacuum-assisted systems representing the largest revenue share. By technique, image-guided biopsy (stereotactic, ultrasound, and MRI-guided) accounts for the majority of procedures. North America leads global revenue due to high screening rates, established reimbursement, and strong clinical infrastructure, while Asia-Pacific is the fastest-growing region, supported by expanding healthcare access and rising cancer awareness.

• •Core needle biopsy and vacuum-assisted biopsy are the leading product segments.
• •Image-guided biopsy is the dominant technique category.
• •North America leads revenue, while Asia-Pacific shows the fastest growth.

What are the recent trends and outlook?

The market is moving toward less invasive, image-guided, and automated biopsy systems that can deliver both diagnosis and, increasingly, excision of benign lesions in a single procedure. Integration with digital breast tomosynthesis, contrast-enhanced mammography, and AI-assisted lesion detection is reshaping clinical workflows. Over the medium term, the combination of demographic pressures, screening expansion in emerging markets, and continued technological innovation is expected to sustain mid-single-digit growth through the next decade.

• •Convergence with digital breast tomosynthesis and AI-assisted lesion detection is accelerating.
• •Vacuum-assisted excision is enabling combined diagnostic and therapeutic procedures.
• •Sustained mid-single-digit growth is expected as screening expands in emerging markets.